<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../images/favicon.png" type="image/x-icon">
  <title>Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="../style.css">
  <link rel="stylesheet" href="../notes.css">

</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="../index.html">
   <div class="home-navigation">
      mtr<span class="logo-dot">.</span>
    </div>
  </a>


    <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="../index.html">Home</a>
      </li>

      <li class="menu__item">
        <a class="menu__link" href="../about-temp2.html">About</a>
      </li>
    </ul>
  </nav>
  
      <!-- Toggle switch for dark mode -->
      <div class="dark-mode-toggle">
        <label class="switch-toggle">
            <input type="checkbox" id="dark-mode-toggle-checkbox">
            <span class="toggle-slider"></span>
        </label>
      </div>

      <!-- Progress Bar  -->
      <div id="progress-container">
        <div id="progress-bar"></div>
    </div>
      
<!-- SIDEBAR -->
<div id="sidebar" class="sidebar">
  <button id="closeSidebarBtn" class="btn toggle-btn close-btn">Close</button>
  <ul class="sidebar-menu toggle-menu">
    <!-- Add the list of topics dynamically using JavaScript -->
  </ul>
</div>

<!-- Toggle button to open the sidebar -->
<button id="toggleSidebarBtn" class="btn toggle-btn">&#9776;</button>

<!-- END OF SIDEBAR -->

  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterüíú</p>
      <span><a href="../contribute.html">Contribute here</a> </span>
    </div>


  <!-- TOPIC AND IMAGE CONTAINER  -->


      <h1>Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)</h1>


  <!-- END OF TOPIC AND IMAGE CONTAINER  -->
  


    <article class="notes">
        <a id='top'></a>
    <article>

          <!-- LEARNING OBJECTIVES CONTAINER  -->
              <div class="custom-card" id="custom-card-1">
                <div class="icon"><img src="../images/icons/light-bulb.png" alt="Icon" class="icon"></div>
                <div class="title"> 
                  <h2>What You Will Learn</h2>
                </div>
                <div class="line">
                  <p>After reading this note, you should be able to...</p>
                </div>
                <div class="content">
                  <ul>
                    <li><i>This content is not available yet.</i></li>
                </ul>
                </div>
                <div class="read-more" onclick="toggleContent('custom-card-1')">Read More üç™</div>
              </div>
            
          <!-- END OF LEARNING OBJECTIVES CONTAINER  -->
        
        
          <!-- SHOW AND HIDE OUTLINE CONTAINER  -->
            <div class="outline2">
        
              <input type="radio" name="control-2" id="show-2">
              <label for="show-2">üêµ&nbsp; &nbsp;Show Outline</label>
              <input type="radio" name="control-2" id="hide-2">
              <label for="hide-2">üôà&nbsp; &nbsp; Hide Outline</label>
              <div class="contents">
                <div class="icon-box">
                  <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                  <img src="../images/icons/book.png" alt="Icon" class="icon">
                </div>
                <div id="tableOfContents">
                    <ol id="tocList"></ol>
                </div>
              </div>
             <div>
        
        <!-- END OF SHOW AND HIDE OUTLINE CONTAINER  -->
        
        
        <!-- READ SUMMARY CONTAINER -->
        
              <!-- Summary Overlay -->
              <div class="summary-overlay" id="summaryOverlay"></div>
        
        
              <div class="summary-card" id="summaryCard">
                
                <div class="summary-header">
                  <h3>Note Summary</h3>
                  <div class="icon-box">
                    <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                    <img src="../images/icons/summary.png" alt="Icon" class="icon">
                  </div>
                </div>
                <div class="summary-content">
                  <!-- Summary content goes here -->
                  <p><i>This content is not available yet.</i></p>
        
                  <span class="close-btn" id="closeBtn">close</span>
                </div>
              </div>
        
              <div class="summary-trigger" id="summaryTrigger">
                <p>Click here to read a summary</p>
            </div>
        <!-- END OF READ SUMMARY CONTAINER -->
        
            <!-- BEGINNING OF NOTE -->
        
      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Causes of Thromboembolism</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li><strong>Inherited</strong></li>
                <li><strong>Acquired</strong></li>
            </ul>


            <section id='heading-1-1'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-1-1'>Inherited VE</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li><strong>Inherited thrombophilia</strong></li>
                        <ul>
                            <li><strong>Factor V Leiden mutation</strong></li>
                            <li><strong>Prothrombin gene mutation</strong></li>
                            <li><strong>Protein S deficiency</strong></li>
                            <li><strong>Protein C deficiency</strong></li>
                            <li><strong>Antithrombin (AT) deficiency</strong></li>
                            <li><strong>Rare disorders</strong></li>
                            <ul>
                                <li><strong>Dysfibrinogenemia</strong></li>
                            </ul>
                        </ul>
                    </ul>
                    
    
                </div>
              </section>

              <section id='heading-1-2'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-1-2'>Acquired VE</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li><strong>Malignancy</strong></li>
                        <li><strong>Presence of a central venous catheter</strong></li>
                        <li><strong>Surgery, especially orthopedic</strong></li>
                        <li><strong>Trauma</strong></li>
                        <li><strong>Pregnancy</strong></li>
                        <li><strong>Oral contraceptives</strong></li>
                        <li><strong>Hormone replacement therapy</strong></li>
                        <li><strong>Tamoxifen, Bevacizumab, Thalidomide, Lenalidomide</strong></li>
                        <li><strong>Immobilization</strong></li>
                        <li><strong>Congestive failure</strong></li>
                        <li><strong>Antiphospholipid antibody syndrome</strong></li>
                        <li><strong>Myeloproliferative disorders</strong></li>
                        <ul>
                            <li><strong>Polycythemia vera</strong></li>
                            <li><strong>Essential thrombocythemia</strong></li>
                            <li><strong>Paroxysmal nocturnal hemoglobinuria</strong></li>
                        </ul>
                        <li><strong>Inflammatory bowel disease</strong></li>
                        <li><strong>Nephrotic syndrome</strong></li>
                        <li><strong>Hyperviscosity</strong></li>
                        <li><strong>Waldenstrom's macroglobulinemia</strong></li>
                        <li><strong>Multiple myeloma</strong></li>
                        <li><strong>Marked leukocytosis in acute leukemia</strong></li>
                        <li><strong>Sickle cell anemia</strong></li>
                        <li><strong>HIV/AIDS</strong></li>
                    </ul>
    
                </div>
              </section>
            


            
        </div>
      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Pathophysiology</a>
          </h2>
        </header>
        <div class='body'>
            <h4></h4>
            <ul>
                <li><strong>VIRCHOW'S TRIAD</strong> ‚Äî proposes that VTE occurs as a result of:</li>
                <ol>
                    <li>Alterations in blood flow (i.e., <strong>stasis</strong>)</li>
                    <li>Vascular endothelial injury</li>
                    <li>Alterations in the constituents of the blood (i.e., inherited or acquired <strong>hypercoagulable state</strong>)</li>
                </ol>
            </ul>
            
            <h4>INITIAL APPROACH</h4>
            <p>When approaching the patient with suspected DVT of the lower extremity, it is important to appreciate that only a minority of patients actually have the disease and will require anticoagulation.</p>
            
        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>DVT History</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li>Classic symptoms of DVT include <strong>swelling</strong>, <strong>pain</strong>, and <strong>discoloration</strong> in the involved extremity.</li>
            </ul>
            <p><strong>NOTE:</strong></p>
            <ul>
                <li>There is no correlation between the location of symptoms and the site of thrombosis.</li>
            </ul>
            <ul>
                <li>Symptoms in the calf alone are often the presenting manifestation of significant proximal vein involvement, while some patients with whole leg symptoms are found to have isolated calf vein DVT.</li>
            </ul>
            
        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>DVT Physical Exam</a>
          </h2>
        </header>
        <div class='body'>
            <h4></h4>
            <p>Many patients are asymptomatic; however, the history may include the following:</p>
            <ul>
                <li><strong>Edema</strong>, principally unilateral, is the most specific symptom.</li>
                <li>Massive edema with cyanosis and ischemia (<strong>phlegmasia cerulea dolens</strong>) is rare.</li>
                <li>Leg pain occurs in 50% of patients, but this is entirely nonspecific.</li>
            </ul>
            
            <h4>Homan‚Äôs sign</h4>
            <ul>
                <li>Pain/discomfort in the calf muscles on forced dorsiflexion of the foot with the knee straight has been a time-honored sign of DVT. However, this sign is present in less than one third of patients with confirmed DVT.</li>
                <li>The Homan‚Äôs sign is found in more than 50% of patients without DVT and, therefore, is nonspecific.</li>
                <ul>
                    <li>Superficial thrombophlebitis is characterized by the finding of a palpable, indurated, cordlike, tender, subcutaneous venous segment.</li>
                    <li>Forty percent of patients with superficial thrombophlebitis without coexisting varicose veins and with no other obvious etiology (e.g., intravenous catheters, intravenous drug abuse, soft tissue injury) have an associated DVT.</li>
                </ul>
            </ul>
            
        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>DVT Differential Diagnosis</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li><strong>Lymphangitis</strong> or lymph obstruction</li>
                <li><strong>Baker's cyst</strong></li>
                <li><strong>Cellulitis</strong></li>
                <li>Muscle strain, tear, or twisting injury to the leg</li>
                <li>Leg swelling in a paralyzed limb</li>
                <li><strong>Knee abnormality</strong></li>
            </ul>
            
        </div>
      </section>

      <section id='header-6'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-6'>DVT Diagnosis</a>
          </h2>
        </header>
        <div class='body'>

            <section id='heading-6-1'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-6-1'> Wells Score</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>The Wells clinical prediction guide quantifies the pretest probability of DVT.</li>
                        <li>The model enables providers to reliably stratify their patients into <strong>high-, moderate-, or low-risk</strong> categories.</li>
                        <li>The Wells clinical prediction guide incorporates risk factors, clinical signs, and the presence or absence of alternative diagnoses.</li>
                        <li><strong>Paralysis, paresis, or recent orthopedic casting</strong> of a lower extremity (1 point)</li>
                        <li><strong>Recently bedridden</strong> for longer than three days or <strong>major surgery</strong> within the past four weeks (1 point)</li>
                        <li><strong>Localized tenderness</strong> in the deep vein system (1 point)</li>
                        <li><strong>Swelling of an entire leg</strong> (1 point)</li>
                        <li>Calf swelling <strong>3cm greater than the other leg</strong>, measured 10cm below the tibial tuberosity (1 point)</li>
                        <li><strong>Pitting edema</strong> greater in the symptomatic leg (1 point)</li>
                        <li><strong>Collateral non-varicose superficial veins</strong> (1 point)</li>
                        <li><strong>Active cancer</strong> or cancer treated within six months (1 point)</li>
                        <li><strong>Alternative diagnosis more likely than DVT</strong> (e.g., Baker's cyst, cellulitis, muscle damage, post-phlebitic syndrome, inguinal lymphadenopathy, external venous compression) (-2 points)</li>
                    </ul>

                    <br>
                    <h4></h4>
                    <table class="note-table">
                        <tr>
                            <th colspan="2" style="text-align: center;">Wells Score</th>
                        </tr>
                        <tr>
                            <th>Clinical Parameter</th>
                            <th>Score</th>
                        </tr>
                        <tr>
                            <td>Active cancer (treatment ongoing, or within 6 mo or palliative)</td>
                            <td>+1</td>
                        </tr>
                        <tr>
                            <td>Paralysis or recent plaster immobilization of the lower extremities</td>
                            <td>+1</td>
                        </tr>
                        <tr>
                            <td>Recently bedridden for &gt;3 d or major surgery &lt;4 wk</td>
                            <td>+1</td>
                        </tr>
                        <tr>
                            <td>Localized tenderness along the distribution of the deep venous system</td>
                            <td>+1</td>
                        </tr>
                        <tr>
                            <td>Entire leg swelling</td>
                            <td>+1</td>
                        </tr>
                        <tr>
                            <td>Calf swelling &gt;3 cm compared with the asymptomatic leg</td>
                            <td>+1</td>
                        </tr>
                        <tr>
                            <td>Pitting edema (greater in the symptomatic leg)</td>
                            <td>+1</td>
                        </tr>
                        <tr>
                            <td>Previous DVT documented</td>
                            <td>+1</td>
                        </tr>
                        <tr>
                            <td>Collateral superficial veins (nonvaricose)</td>
                            <td>+1</td>
                        </tr>
                        <tr>
                            <td>Alternative diagnosis (as likely or greater than that of DVT)</td>
                            <td>-2</td>
                        </tr>
                        <tr>
                            <td colspan="2">
                                Total of Above Score:
                                <ul>
                                    <li>High probability: &gt;3</li>
                                    <li>Moderate probability: 1 or 2</li>
                                    <li>Low probability: &lt;0</li>
                                </ul>
                            </td>
                        </tr>
                    </table>
                    

                    
                </div>
              </section>

              <section id='heading-6-2'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-6-2'>DVT D-dimer</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>D-dimer fibrin fragments are present in fresh fibrin clot and in fibrin degradation products of cross-linked fibrin.</li>
                        <li>Monoclonal antibodies specific for the D-dimer fragment are used to differentiate fibrin-specific clot from non‚Äìcross-linked fibrin and from fibrinogen.</li>
                        <li>D-dimer level may be elevated in any medical condition where clots form.</li>
                        <li>D-dimer level is elevated in trauma, recent surgery, hemorrhage, cancer, and sepsis.</li>
                        <li>Many of these conditions are associated with higher risk for DVT.</li>
                    </ul>
                    
                    <h4>Medical Conditions Associated With an Elevated D-dimer</h4>
                    <p>Arterial thromboembolic disease</p>
                    <ul>
                        <li>Myocardial infarction</li>
                        <li>Stroke</li>
                        <li>Acute limb ischemia</li>
                        <li>Atrial fibrillation</li>
                        <li>Intracardiac thrombus</li>
                    </ul>
                    
                    <p>Venous thromboembolic disease</p>
                    <ul>
                        <li>Deep vein thrombosis</li>
                        <li>Pulmonary embolism</li>
                        <li>Disseminated intravascular coagulation</li>
                        <li>Preeclampsia and eclampsia</li>
                        <li>Abnormal fibrinolysis; use of thrombolytic agents</li>
                    </ul>
                    
                    <h4>D-dimer results should be used as follows:</h4>
                    <ul>
                        <li>A negative D-dimer assay result rules out DVT in patients with low-to-moderate risk and a Wells DVT score less than 2.</li>
                        <li>All patients with a positive D-dimer assay result and all patients with a moderate-to-high risk of DVT (Wells DVT score &gt;2) require a diagnostic study (duplex ultrasonography).</li>
                    </ul>
                    
                    <p>A D-dimer level less than 200 to 500 ng/mL by ELISA or a negative SimpliRED assay in conjunction with a low clinical probability of DVT appears to be useful and cost-effective in excluding DVT without the need for an ultrasound examination.</p>
                    
                </div>
              </section>

              <section id='heading-6-3'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-6-3'>Compression Ultrasonography</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>In most circumstances, compression ultrasonography is the noninvasive approach of choice for the diagnosis of patients with suspected DVT.</li>
                        <li>If unavailable, impedance plethysmography with serial studies is an acceptable alternative.</li>
                        <li>One exception noted above is that impedance plethysmography is preferred for possible recurrent DVT since it normalizes more quickly after a previous episode than compression ultrasonography.</li>
                    </ul>
                    
                    <p>The diagnosis of venous thrombosis using compression ultrasonography is made by the findings such as:</p>
                    <ul>
                        <li>Abnormal compressibility of the vein</li>
                        <li>Abnormal Doppler color flow</li>
                        <li>The presence of an echogenic band</li>
                        <li>Abnormal change in diameter during the Valsalva maneuver</li>
                    </ul>
                    
    
                </div>
              </section>

              <section id='heading-6-4'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-6-4'>MRI</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>MRI is the diagnostic test of choice for suspected iliac vein or inferior vena caval thrombosis when CT venography is contraindicated or technically inadequate.</li>
                        <li>In the second and third trimester of pregnancy, MRI is more accurate than duplex ultrasonography because the gravid uterus alters Doppler venous flow characteristics.</li>
                        <li>Expense, lack of general availability, and technical issues limit its use.</li>
                    </ul>
                    
    
                </div>
              </section>


            
        </div>
      </section>

      <section id='header-7'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-7'>Treatment of DVT </a>
          </h2>
        </header>
        <div class='body'>
            <p>The primary objectives of Rx of DVT are to prevent and/or treat:</p>
            <ul>
                <li><strong>further clot extension</strong></li>
                <li><strong>acute pulmonary embolism</strong></li>
                <li><strong>the risk of recurrent thrombosis</strong></li>
                <li><strong>the development of late complications</strong>, such as the <strong>postphlebitic syndrome</strong>, <strong>chronic venous insufficiency</strong>, and <strong>chronic thromboembolic pulmonary HPTN</strong>.</li>
            </ul>
            <p><strong>Anticoagulant therapy</strong> is indicated for patients with symptomatic proximal DVT, since pulmonary embolism will occur in about <strong>50 percent</strong> of untreated individuals, most often within <strong>days or weeks</strong> of the event.</p>
            <p>The use of <strong>thrombolytic agents</strong>, <strong>surgical thrombectomy</strong>, or <strong>percutaneous mechanical thrombectomy</strong> in the treatment of venous thromboembolism must be individualized.</p>
            <p>Patients with <strong>hemodynamically unstable PE</strong> or <strong>massive iliofemoral thrombosis</strong> and who are also at <strong>low risk to bleed</strong>, are the most appropriate candidates for such treatment.</p>
            

                <p>Inferior vena caval filter placement is recommended when there is a contraindication to, or a failure of, anticoagulant therapy. It is also recommended in patients with recurrent thromboembolism despite adequate anticoagulation.</p>
            
            
            <p><strong>Oral anticoagulation</strong> with warfarin should prolong the INR to a target of <strong>2.5</strong> (range: <strong>2.0 to 3.0</strong>).</p>
            <p>If oral anticoagulants are contraindicated or inconvenient, long-term therapy can be undertaken with either adjusted-dose unfractionated heparin, low molecular weight heparin, or fondaparinux.</p>
            <p>Once anticoagulation has been started and the patient's symptoms (i.e., pain, swelling) are under control, <strong>early ambulation</strong> is advised.</p>
            <p>During initial ambulation, and for the first two years following an episode of VTE, use of an <strong>elastic compression stocking</strong> has been recommended to prevent the postphlebitic syndrome.</p>
            
        </div>
      </section>

      <section id='header-8'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-8'>PE Classification </a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li>Acute vs. chronic</li>
                <li>Massive vs. submassive</li>
            </ul>
            
            <ul>
                <li>A <strong>saddle PE</strong> is a PE that lodges at the bifurcation of the main pulmonary artery into the right and left pulmonary arteries.</li>
                <li>Most saddle PE are <strong>submassive</strong>.</li>
                <li>In a retrospective study of <strong>546</strong> consecutive patients with PE, <strong>14</strong> (2.6 percent) had a saddle PE.</li>
                <li>Only <strong>two</strong> of the patients with saddle PE had hypotension.</li>
            </ul>
            
        </div>
      </section>

      <section id='header-9'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-9'> PE Prognosis</a>
          </h2>
        </header>
        <div class='body'>
            <p><strong>Poor Prognosis:</strong></p>
            <ul>
                <li>Elevated <strong>Brain Natriuretic Peptide (BNP)</strong></li>
                <li>Right Ventricular dysfunction</li>
                <li>Hypotension</li>
                <li>RV thrombus</li>
                <li>Elevated <strong>Troponin I</strong></li>
            </ul>
            
            
        </div>
      </section>

      <section id='header-10'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-10'> PE Pathophysiology</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li>Most PE arise from thrombi in the deep venous system of the lower extremities. However, they may also originate in the right heart or the pelvic, renal, or upper extremity veins.</li>
                <li>Iliofemoral veins are the source of most clinically recognized PE.</li>
                <li>It is estimated that <strong>50 to 80 percent</strong> of iliac, femoral, and popliteal vein thrombi (proximal vein thrombi) originate below the popliteal vein (calf vein thrombi) and propagate proximally.</li>
                <li>The remainder arise within the proximal veins.</li>
                <li>Fortunately, most calf vein thrombi resolve spontaneously and only <strong>20 to 30 percent</strong> extend into the proximal veins if untreated.</li>
                <li>After traveling to the lung, large thrombi may lodge at the bifurcation of the main pulmonary artery or the lobar branches and cause hemodynamic compromise.</li>
                <li>Smaller thrombi continue traveling distally and are more likely to produce pleuritic chest pain, presumably by initiating an inflammatory response adjacent to the parietal pleura.</li>
                <li>Only about <strong>10 percent</strong> of emboli cause pulmonary infarction, usually in patients with preexisting cardiopulmonary disease.</li>
                <li>Most pulmonary emboli are multiple, with the lower lobes being involved in the majority of cases.</li>
            </ul>
            
        </div>
      </section>

      <section id='header-11'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-11'>PE Risk Factors </a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li>PE is a common complication of deep vein thrombosis (DVT), occurring in more than <strong>50 percent</strong> of cases with phlebographically confirmed DVT.</li>
                <li>This suggests that factors that promote the development of DVT also increase the risk for PE.</li>
            </ul>
            
            <h4>PE Additional Risks Factors in Women</h4>
            <ul>
                <li>Obesity (BMI ‚â•<strong>29 kg/m2</strong>)</li>
                <li>Heavy cigarette smoking (>25 cigarettes per day)</li>
                <li>Hypertension</li>
            </ul>
            
        </div>
      </section>

      <section id='header-12'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-12'> PE Diagnosis</a>
          </h2>
        </header>
        <div class='body'>
            <section id='heading-12-1'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-12-1'>PE Labs</a>
                  </h3>
                </header>
                <div class='body'>
                    <h4></h4>
                    <p>Routine laboratory findings are nonspecific.</p>
                    <ul>
                        <li>Leukocytosis</li>
                        <li>An increased erythrocyte sedimentation rate (<strong>ESR</strong>)</li>
                        <li>Elevated serum <strong>LDH</strong> or <strong>AST</strong> (<strong>SGOT</strong>)</li>
                        <li>Normal serum bilirubin.</li>
                    </ul>
                    
    
                </div>
              </section>

              <section id='heading-12-2'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-12-2'>PE Arterial Blood Gases (ABG‚Äôs)</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>Arterial blood gas (ABG) measurements and pulse oximetry have a limited role in diagnosing PE.</li>
                        <li>ABG‚Äôs usually reveal <strong>hypoxemia</strong>, <strong>hypocapnia</strong>, and <strong>respiratory alkalosis</strong>.</li>
                    </ul>
                    
    
                </div>
              </section>

              <section id='heading-12-3'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-12-3'>Venous Ultrasound</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>Lower extremity venous ultrasound is sometimes performed during the diagnostic evaluation of PE.</li>
                        <li>The rationale is that venous thrombosis detected by ultrasound is treated similar to confirmed PE.</li>
                    </ul>
                    
    
                </div>
              </section>

              <section id='heading-12-4'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-12-4'>D-dimer Sensitivity</a>
                  </h3>
                </header>
                <div class='body'>
                    <p>D-dimer levels are abnormal in approximately <strong>95 percent</strong> of all patients with PE when measured by ELISA, quantitative rapid ELISA, or semi-quantitative rapid ELISA.</p>
                    
                    
    
                </div>
              </section>

              <section id='heading-12-5'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-12-5'>CXR</a>
                  </h3>
                </header>
                <div class='body'>
                        <ul>
                            <li>Normal</li>
                            <li>Atelectasis and/or pulmonary parenchymal abnormality</li>
                            <li>Pleural Effusion</li>
                            <li>Cardiomegally</li>
                        </ul>
                    
    
                </div>
              </section>

              <section id='heading-12-6'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-12-6'>ECG Changes</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>‚ÄúS1 Q3 T3‚Äù</li>
                        <li>S wave in lead I</li>
                        <li>Q wave in lead III</li>
                        <li>Flipped T in lead III</li>
                        <li>Possible <strong>RBBB</strong></li>
                        <li>Signs of <strong>cor pulmonale</strong></li>
                        <li>Classic, but uncommon</li>
                    </ul>
                    
    
                </div>
              </section>

              <section id='heading-12-7'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-12-7'>VQ scan</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>Started in <strong>1960s</strong></li>
                        <li>Correlated well with angiogram and autopsy</li>
                        <li>‚ÄúHigh probability‚Äù scans: <strong>41%</strong> sensitive, <strong>97%</strong> specific</li>
                        <li>Adequate for diagnosis in a minority of patients</li>
                    </ul>
                    
    
                </div>
              </section>

              <section id='heading-12-8'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-12-8'>Spiral CT</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>Spiral (helical) CT scanning with intravenous contrast (i.e., CT pulmonary angiography or CT-PA) is being used increasingly as a diagnostic modality for patients with suspected PE.</li>
                        <li>One of the most commonly cited benefits of CT-PA is the ability to detect alternative pulmonary abnormalities that may explain the patient's clinical presentation.</li>
                    </ul>
                    
                    <h4>CT Chest</h4>
                    <ul>
                        <li>Spiral CT chest introduced in early <strong>1990s</strong></li>
                        <li>Sensitivity <strong>86-100%</strong>, specificity <strong>92-96%</strong> for central PE</li>
                        <li><strong>63%</strong> sensitive for subsegmental PE</li>
                    </ul>
                    
    
                </div>
              </section>

              <section id='heading-12-9'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-12-9'>Pulmonary Angiography</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>Started in <strong>1950s</strong></li>
                        <li><strong>47%</strong> positive studies had no signs on CXR</li>
                        <li>1st confirmatory test other than autopsy</li>
                    </ul>
                    

                    
                </div>
              </section>

              <section id='heading-12-10'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-12-10'>ECHO for PE</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>RV dilates and LV is smaller in most patients</li>
                        <li>Unreliable in pts with prior cardiac dysfunction</li>
                        <li>TEE reported to be <strong>&gt;90%</strong> sensitive and specific</li>
                        <li>Right heart dysfunction resolves after thrombolytic therapy</li>
                    </ul>
    
                </div>
              </section>
        </div>
      </section>

      <section id='header-13'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-13'> Pathophysiology of PE on the Cardiopulmonary System</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li>PE are usually multiple and preferentially in the lower lobes.</li>
                <li>As clot burden increases, hypoxia increases. Hypercapnia and acidosis are rare.</li>
                <li>With increased pulmonary vascular resistance secondary to obstruction, hypotension can develop.</li>
                <li>This in turn obstructs right ventricular outflow which then causes right ventricular dilation (often with flattening and even bulging of the septum into the left ventricle).</li>
                <li>Reduced flow from the right ventricle in turn decreases cardiac output from the left ventricle, all of which results in hypotension then cardiac arrest and death.</li>
            </ul>
            
        </div>
      </section>

      <section id='header-14'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-14'>Treatment of P.E. </a>
          </h2>
        </header>
        <div class='body'>
            <ul>
                <li>Respiratory Support: Oxygen, intubation</li>
                <li>Hemodynamic Support: IVF, vasopressors</li>
                <li>Anticoagulation</li>
                <li>Thrombolysis</li>
                <li>IVC Filter</li>
            </ul>
            
            <section id='heading-14-1'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-14-1'>Anticoagulation</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>Start during resuscitation phase itself</li>
                        <li>If suspicion high, start empiric anticoagulation</li>
                        <li>Evaluate patient for absolute contraindication (i.e.: active bleeding)</li>
                        <li><strong>HEPARIN:</strong></li>
                        <ul>
                            <li>Lovenox: if hemodynamically stable, no renal function impairment</li>
                            <ul>
                                <li>1mg/kg BID <strong>OR</strong> 1.5mg/kg QDay</li>
                            </ul>
                            <li>Heparin gtt: if hypotension, renal failure</li>
                            <ul>
                                <li>80units/kg bolus then 18units/kg infusion</li>
                            </ul>
                            <li>Goal PTT 1.5 to 2.5 times the upper limit of normal</li>
                        </ul>
                        <li><strong>COUMADIN:</strong></li>
                        <ul>
                            <li>Start once acute anticoagulation achieved</li>
                            <li>Start with 5mg PO qday <strong>OR</strong> 10mg PO q day</li>
                            <li>If start with 10mg then achieve therapeutic INR 1.4 days sooner</li>
                            <li>Complications and morbidity no different in 5mg or 10mg start - Goal INR 2 to 3</li>
                        </ul>
                    </ul>
                    
                    <table class="note-table">
                        <tr>
                            <th colspan="3" style="text-align: center;">Duration of Anticoagulation for DVT or PE*</th>
                        </tr>
                        <tr>
                            <th>Event</th>
                            <th>Duration</th>
                            <th>Strength of Recommendation</th>
                        </tr>
                        <tr>
                            <td>First Time event of Reversible cause (surgery/trauma)</td>
                            <td>At least 3 mos</td>
                            <td>A</td>
                        </tr>
                        <tr>
                            <td>First episode of idiopathic VTE</td>
                            <td>At least 6 mos</td>
                            <td>A</td>
                        </tr>
                        <tr>
                            <td>Recurrent idiopathic VTE or continuing risk factor (e.g., thrombophilia, cancer)</td>
                            <td>At least 12 mos</td>
                            <td>B</td>
                        </tr>
                        <tr>
                            <td>Symptomatic isolated calf-vein thrombosis</td>
                            <td>6 to 12 weeks</td>
                            <td>A</td>
                        </tr>
                        <tr>
                            <td colspan="3">*From American College of Chest Physicians</td>
                        </tr>
                    </table>
                    
                </div>
              </section>

              <section id='heading-14-2'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-14-2'>Thrombolysis</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>Considered once P.E. diagnosed</li>
                        <li>If chosen, hold anticoagulation during thrombolysis infusion, then resumed</li>
                        <li>Associated with higher incidence of major hemorrhage</li>
                        <li>Indications: persistent hypotension, severe hypoxemia, large perfusion defects, right ventricular dysfunction, free-floating right ventricular thrombus, patent foramen ovale</li>
                        <li>Activase or streptokinase</li>
                    </ul>
                    
    
                </div>
              </section>

              <section id='heading-14-3'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-14-3'>IVC Filter</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>Indication:</li>
                        <ul>
                            <li>Absolute contraindication to anticoagulation (i.e. active bleeding)</li>
                            <li>Recurrent PE during adequate anticoagulation</li>
                            <li>Complication of anticoagulation (severe bleeding)</li>
                        </ul>
                        <li>Also:</li>
                        <ul>
                            <li>Patients with poor cardiopulmonary reserve</li>
                            <li>Recurrent P.E. will be fatal</li>
                            <li>Patients who have had embolectomy</li>
                            <li>Prophylaxis against P.E. in select patients (malignancy)</li>
                        </ul>
                    </ul>
                    
    
                </div>
              </section>

              <section id='heading-14-4'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-14-4'>Embolectomy</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                        <li>Surgical or catheter</li>
                        <li>Indication:</li>
                        <ul>
                            <li>Those who present severe enough to warrant thrombolysis</li>
                            <li>In those where thrombolysis is contraindicated or fails</li>
                        </ul>
                    </ul>
                    
    
                </div>
              </section>
        </div>
      </section>






      <hr style="margin: 3rem 0;">

      <!-- PRACTICE QUESTIONS CONTAINER -->

      <div class="custom-card" id="custom-card-2">
        <div class="icon"><img src="../images/icons/practice-questions.png" alt="Icon" class="icon"></div>
        <div class="title"> 
          <h2>Practice Questions</h2>
        </div>
        <div class="line">
          <p>Check how well you grasp the concepts by answering the following questions...</p>
        </div>
        <div class="content">
          <ol>
            <li><i>This content is not available yet.</i></li>
          </ol>
        </div>
        <div class="read-more" onclick="toggleContent('custom-card-2')">Read More üç™</div>
      </div>

      <!-- END OF PRACTICE QUESTIONS CONTAINER -->


      <!-- CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
      <div class="contact">
        <div class="comment-container">
          <div class="comment-icon">
            <!-- Add your icon image here -->
            <img src="../images/icons/comment.png" alt="Comment Icon">
          </div>
          <div class="comment-text">
            <!-- Add your text here -->
            <p>Send your comments, corrections, explanations/clarifications and requests/suggestions </p>
          </div>
          <a href="https://chat.whatsapp.com/FtDdb6uEFYzBCnTnMgm2Z1" class="comment-button">
            here
            <img src="../images/icons/whatsapp.png" alt="Image Icon">
          </a>
        </div>

        <div class="contributors-container">

          <h2 class="contributors-header">Contributors</h2>
  
        <br>
            <div class="contributor-box">
                <img class="contributor-avatar" src="../images/icons/woman.png" alt="Contributor 1 Avatar">
                <div class="contributor-info">
                    <h3 class="contributor-name">Jane Smith</h3>
                    <p class="contributor-description">She is not a real contributor.</p>
                    <div class="social-links">
                        <a href="#" target="_blank" class="social-icon">
                            <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                        </a>
                        <a href="#" target="_blank" class="social-icon">
                            <img src="../images/icons/twitter.png" alt="Social Icon 2">
                        </a>
                    </div>
                </div>
            </div>
        
            <div class="contributor-box">
                <img class="contributor-avatar" src="../images/icons/man.png" alt="Contributor 2 Avatar">
                <div class="contributor-info">
                    <h3 class="contributor-name">John Doe</h3>
                    <p class="contributor-description">He is not a real contributor.</p>
                    <div class="social-links">
                      <a href="#" target="_blank" class="social-icon">
                        <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                    </a>
                    <a href="#" target="_blank" class="social-icon">
                        <img src="../images/icons/linkedin.png" alt="Social Icon 2">
                    </a>
                    </div>
                </div>
            </div>
        
        </div>
      </div>

            <!-- END OF CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p id="popup-trigger">disclaimer</p>

          <!-- The pop-up dive content -->
          <div id="popup" class="popup">
            <p>The contents on this ‚Äòwebsite‚Äô are for educational purposes only. The creators and operators of this website make no warranties, express or implied, regarding the accuracy, currency, or completeness of the information provided on the website. They shall not be held responsible for any errors or omissions, or for any actions taken based on the information provided on this website.</p>
            <button class="popup-close" onclick="closePopup()">Close</button>
          </div>    
          <p><a href="../about-temp2.html">about</a> </p>   
          <p><a href="../contribute.html">contribute</a> </p>
          <p><a href="https://chat.whatsapp.com/FtDdb6uEFYzBCnTnMgm2Z1">say hiüëã</a> </p>
        </div>

        <div class="footer-beta">
          <p>thisisatestversion</p>
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="../main.js"></script>
<script src="../modal.js"></script>
<script src="../notes-sidebar.js"></script>
</body>
</html>
 
